A newly approved indication for tocilizumab is the first FDA-approved treatment for giant cell arteritis, a form of vasculitis.
“We expedited the development and review of this application because this drug fulfills a critical need for patients with this serious disease who had limited treatment options,” Badrul Chowdhury, MD, PhD, director of the FDA’s Division of Pulmonary, Allergy, and Rheumatology Products, said in a statement.
Voelker R. A First for Giant Cell Arteritis. JAMA. 2017;318(1):20. doi:10.1001/jama.2017.7639